Upregulation of CD38 has been implicated as a mechanism of resistance to anti–programmed death receptor 1 (anti-PD1) treatment in both non–small cell lung cancer (NSCLC) and melanoma cell lines (13). Here, CD38 is linked to non-small cell lung carcinoma.